Andere Sprachen Gentian Diagnostics

Aktien

A2DLP7

NO0010748866

GENT

Markt geschlossen - Oslo Bors Andere Börsenplätze 16:45:00 28.06.2024			% 5 Tage	% 1. Jan.
54 ^NOK	+20,00 %		+28,57 %	+30,12 %

30.04.	Gentian Diagnostics ASA meldet Ergebnis für das erste Quartal zum 31. März 2024	CI
30.04.	Transcript : Gentian Diagnostics ASA, Q1 2024 Earnings Call, Apr 30, 2024

Andere Sprachen

Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!

100% kostenlose Registrierung

Gentian Diagnostics : Groundbreaking assay development for measuring total NT-proBNP levels	28.06.
Gentian Diagnostics: NT-proBNP successful completion of optimisation phase	28.06.
Gentian Diagnostics : Production assistant - HQ based in Moss, Norway	13.05.
Gentian Diagnostics : Application Sales Specialist (US based)	13.05.
Gentian Diagnostics ASA Reports Earnings Results for the First Quarter Ended March 31, 2024	30.04.
Gentian Diagnostics : 30 April 2024 - Quarterly Presentation - Q1 2024	30.04.
Gentian Diagnostics : 30 April 2024 - Quarterly Report - Q1 2024	30.04.
Gentian Diagnostics Asa Resolves to Elect Ms. Hilja Ibert as Chairperson of the Board of Directors	29.04.
Gentian Diagnostics ASA Appoints Mr. Njaal Kind as Acting CEO	29.04.
Gentian Diagnostics: New acting CEO and Chairperson of the Board of Directors	29.04.
Gentian Diagnostics : Scientists to Gentian’s R&D department	08.04.
Gentian Diagnostics ASA Announces Resignation of Hilja Ibert as CEO, Effective on April 29, 2024	21.03.
Tomas Settevik Not to Stand for Re-Election as Chairperson of Gentian Diagnostics ASA, Effective April 29, 2024	21.03.
Gentian Diagnostics' CEO Resigns, Wins Recommendation to Succeed Chair	21.03.
Gentian Diagnostics ASA Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	09.02.
Gentian Diagnostics Asa Announces Resignation of Frank Frantzen from the Board of Directors	18.12.
Gentian Diagnostics presents at the DNB Nordic Healthcare Conference	14.12.
Gentian Diagnostics ASA Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	26.10.23
Gentian Diagnostics : Sales and Application Specialist - Nordic	10.10.23
Gentian Diagnostics ASA Expands Product Portfolio With Turbidimetric Retinol-Binding Protein Immunoassay	29.09.23

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Gentian Diagnostics

Aktien

A2DLP7

NO0010748866

GENT

Andere Sprachen

Filter